These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 101503)

  • 1. Rifampicin plus nalidixic acid: a rational combination for the treatment of urinary infection.
    Greenwood D; Andrew J
    J Antimicrob Chemother; 1978 Nov; 4(6):533-8. PubMed ID: 101503
    [No Abstract]   [Full Text] [Related]  

  • 2. [Microbiological studies on the combination effect of rifampicin and nalidixic acid (author's transl)].
    Ishiyama M; Nakazawa S
    Jpn J Antibiot; 1974 Oct; 27(5):643-52. PubMed ID: 4218271
    [No Abstract]   [Full Text] [Related]  

  • 3. Nalidixic acid and oxolinic acid in the treatment of chronic bacteriuria.
    Atlas E; Clark H; Silverblatt F; Turck M
    Ann Intern Med; 1969 Apr; 70(4):713-21. PubMed ID: 4977045
    [No Abstract]   [Full Text] [Related]  

  • 4. Trimethoprim in the treatment and long-term control of urinary tract infection.
    Kasanen A; Toivanen P; Sourander L; Kaarsalo E; Aantaa S
    Scand J Infect Dis; 1974; 6(1):91-6. PubMed ID: 4208208
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical value of sensitivity determinations in treating urinary tract infections.
    Fair WR; Fair WR
    Urology; 1982 May; 19(5):565-9. PubMed ID: 7043860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of antiseptic bladder washout procedures using a physical model of the catheterised bladder.
    Stickler DJ; Clayton CL; Chawla JC
    Br J Urol; 1987 Nov; 60(5):413-8. PubMed ID: 3122868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antibacterial effect of rifampicin and its chemotherapeutic properties in experiments on animals].
    Shorin VA; Shapovalova SP; Malkova IV
    Antibiotiki; 1974 Dec; 19(12):1084-8. PubMed ID: 4155605
    [No Abstract]   [Full Text] [Related]  

  • 8. The responses of Escherichia coli to nalidixic acid.
    Greenwood D; O'Grady F
    Chemotherapy; 1978; 24(4):249-58. PubMed ID: 348417
    [No Abstract]   [Full Text] [Related]  

  • 9. [Nalidixic acid].
    Pagnini G
    Antibiotica; 1967 Jun; 5(2):134-59. PubMed ID: 4389549
    [No Abstract]   [Full Text] [Related]  

  • 10. [Study of nalidixic acid activity on 3186 strains of Gram negative bacilli. Application to the treatment of urinary infections].
    Chamfeuil R; Curcier H
    Presse Med (1893); 1969 Nov; 77(48):1763-4. PubMed ID: 4903534
    [No Abstract]   [Full Text] [Related]  

  • 11. Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistance.
    Greenwood D; Osman M; Goodwin J; Cowlishaw WA; Slack R
    J Antimicrob Chemother; 1984 Apr; 13(4):315-23. PubMed ID: 6233248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nalidixic acid in urinary infection.
    Neogy KN; De MS; Chatterjee ML
    Bull Calcutta Sch Trop Med; 1968 Jan; 16(1):11-2. PubMed ID: 4890385
    [No Abstract]   [Full Text] [Related]  

  • 13. Bacteriological and clinical evaluation of the combination of cloxacillin with ampicillin.
    Klastersky J; Debusscher L; Rühl D
    Chemotherapy; 1972; 17(6):382-91. PubMed ID: 4628324
    [No Abstract]   [Full Text] [Related]  

  • 14. [Resistance to rifampicin. In vitro and in vivo studies].
    Bouanchaud DH; Acar JF
    Pathol Biol (Paris); 1969; 17(15):763-7. PubMed ID: 4907911
    [No Abstract]   [Full Text] [Related]  

  • 15. [Studies on combined action of ampicillin and neggram on gram-negative rods].
    Dzierzanowska D; Bobrowski M; Boroń-Kaczmarska A
    Wiad Lek; 1971 Mar; 24(5):421-6. PubMed ID: 4928217
    [No Abstract]   [Full Text] [Related]  

  • 16. Factors governing the emergence of resistance to nalidixic acid in treatment of urinary tract infection.
    Greenwood D; O'Grady F
    Antimicrob Agents Chemother; 1977 Dec; 12(6):678-81. PubMed ID: 337890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibilities of canine urinary bacteria to selected antimicrobial agents.
    Rohrich PJ; Ling GV; Ruby AL; Jang SS; Johnson DL
    J Am Vet Med Assoc; 1983 Oct; 183(8):863-7. PubMed ID: 6415021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nalidixic acid.
    Bailey RR
    JAMA; 1977 Jun; 237(25):2720. PubMed ID: 577224
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antibacterial in-vitro activity of pipemidic acid and nalidixic acid (author's transl)].
    Peters G; Freiesleben H; Marre R; Metz H; Tannenberg H; Pulverer G
    Dtsch Med Wochenschr; 1979 Jun; 104(26):946-8. PubMed ID: 110574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pattern of antimicrobial susceptibility in uropathogen isolates from children].
    Suárez VM; Suárez RC; Pérez BA; Alvarez FA; Castro SP; Rodríguez FS; Guerrero SM
    Rev Esp Quimioter; 2001 Mar; 14(1):63-8. PubMed ID: 11376352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.